top of page

Weekly Newsletter (10/13) - Survey Reveals Why Most Americans Won’t Try GLP-1 Weight Loss Drugs

Topic of the Month on ModernWeight: Redefining Weight Management Together: Let's Talk Stigma and Solutions

Head to the Social Hub to share your success story or learn about others.



AOMs in the News


This Week's Featured Post

Survey Finds Most Americans Wouldn’t Use GLP-1 Drugs for Weight Loss


In this week’s featured post, a new survey reveals that despite the growing popularity of GLP-1 drugs for weight loss, most Americans would not take them. The survey found that cost, concerns about long-term safety, and fear of side effects were the main reasons people were hesitant to try medications like Ozempic and Wegovy. The findings underscore the divide between those who view these drugs as breakthrough treatments and those who remain wary of their impact.



The survey results come at a time when GLP-1 drugs are gaining traction as effective solutions for weight management. However, many individuals are left without access to limited insurance coverage and high out-of-pocket costs. Additionally, some respondents expressed concerns about the need to remain on these medications long-term to maintain weight loss, further fueling skepticism about their practicality.


Why It Matters:

While GLP-1 drugs have shown significant success in helping patients lose weight, these survey results highlight a larger conversation about accessibility, cost, and patient confidence in new treatments. As the demand for weight loss solutions grows, it’s crucial to address the concerns of the broader population to ensure that those who can benefit from GLP-1s feel comfortable seeking out these medications.


Only 1 in 5 Large Companies' Health Plans Cover New Weight-Loss Meds for Employees


A recent report shows that only 20% of large U.S. companies currently offer health plans that cover GLP-1 weight-loss medications like Ozempic and Wegovy. Many companies cite the high costs of these drugs as the primary barrier to inclusion in their health plans. While some employers are exploring alternative options, like partnering with wellness programs, most have yet to incorporate these medications into their benefits packages.


Why It Matters:

With obesity rates rising across the country, the limited coverage of weight-loss medications by large employers is a significant concern. Expanding access to GLP-1 drugs through employer-sponsored health plans could help more individuals manage their weight and reduce related healthcare costs, but current coverage gaps may leave many employees without this critical option.


Balancing the Costs of GLP-1 Weight Loss Drug Coverage: New CBO Report Has Some Answers


A new report from the Congressional Budget Office (CBO) provides insights into the economic challenges of covering GLP-1 weight-loss medications under government-funded health programs. According to the report, adding GLP-1s to Medicaid or Medicare coverage would significantly increase short-term costs. However, the potential long-term benefits, such as reduced hospitalizations and improved overall health outcomes, could outweigh these initial expenses.


Why It Matters:

The CBO's findings could influence policy decisions about expanding coverage for GLP-1 medications in public health programs. If lawmakers decide to prioritize these drugs, millions of Americans could gain access to life-changing treatments. However, balancing the upfront costs with long-term health benefits will remain a central debate.


How Might GLP-1 Drugs Like Ozempic and Wegovy Benefit the Brain?


In addition to their well-known effects on weight loss and diabetes, GLP-1 drugs like Ozempic and Wegovy may also provide cognitive benefits. New research suggests that these medications could help protect against neurodegenerative diseases, including Alzheimer’s and Parkinson’s. The potential for GLP-1s to improve brain health has led to increased interest in their broader applications beyond metabolic disorders.


Why It Matters:

This new avenue of research positions GLP-1 medications as more than just weight-loss drugs. If further studies confirm these findings, GLP-1s could become part of the treatment landscape for various neurological conditions, opening new possibilities for improving brain health while managing weight and diabetes.


WeightWatchers' Stock Soars After Adding Compounded GLP-1 Treatment to Its Offering


WeightWatchers saw its stock rise sharply after announcing that it would begin offering compounded GLP-1 treatments through its weight-loss programs. This move follows an increasing trend of companies incorporating GLP-1 medications to enhance their wellness offerings. WeightWatchers aims to provide a more affordable and accessible option by partnering with compounders to offer these medications at lower costs than traditional GLP-1 drugs.


Why It Matters:

By offering compounded GLP-1 treatments, WeightWatchers is capitalizing on the growing demand for weight-loss medications while addressing the accessibility and affordability concerns many people face. This development signals the expanding role that GLP-1 drugs may play in mainstream weight-management programs, potentially reshaping the industry.

---


Expert Tweet of the Week


From @TheLancet


"Obesity is a growing global epidemic with major health consequences. Bariatric surgery is the most effective treatment, with progress in the development of pharmacological agents. However, all obesity treatments have been underutilised."


Related Article: The Lancet


---


Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.


Want to receive this newsletter in your inbox weekly? Create a profile!



2 views0 comments

Comments


bottom of page